Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
Open Access
- 1 October 2020
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Ophthalmology
- Vol. 50 (5) , 275-282
Abstract
Objectives: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. Materials and Methods: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. Results: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p<0.001) and 5 subgroups were identified. Conclusion: Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features.Keywords
This publication has 31 references indexed in Scilit:
- Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)Clinical Ophthalmology, 2013
- Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapyBritish Journal of Ophthalmology, 2013
- CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICERetina, 2013
- Anti-VEGF Treatment Strategies for Wet AMDJournal of Ophthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degenerationJapanese Journal of Ophthalmology, 2010
- Hemoglobin Expression and Regulation in Glaucoma: Insights into Retinal Ganglion Cell OxygenationInvestigative Ophthalmology & Visual Science, 2010
- TACHYPHYLAXIS AFTER INTRAVITREAL BEVACIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATIONRetina, 2009
- Quantitative Subanalysis of Optical Coherence Tomography after Treatment with Ranibizumab for Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2008
- Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBritish Journal of Ophthalmology, 2007